Business Standard

Bharat Biotech seeks nod for phase-3 clinical trials of nasal vaccine

The Hyderabad-based vaccine maker conducted phase 2 trials on 650 volunteers

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Sohini Das Mumbai
Covaxin maker Bharat Biotech has sought approval to start phase-3 clinical trials for its intranasal Covid-19 vaccine candidate BBV154 from India’s drug regulator. The company plans to administer the nasal vaccine as a booster dose for those who have already received two shots of any Covid vaccine, sources revealed.

A company source said, “We have submitted a phase 3 clinical trial application to DCGI. An intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns. Intranasal vaccines have the potential to prevent transmission.”

Details about the size of the phase 3 clinical trial are not

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 21 2021 | 2:46 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com